Who founded Abintus Bio?

Abintus Bio was founded by Douglas J. Jolly in 2020.

Who are Abintus Bio's investors?

Abintus Bio's investors include BioBrit, Takeda Ventures.

How much funding has Abintus Bio raised?

Abintus Bio has disclosed $13.7M raised across 1 round.

Where is Abintus Bio headquartered?

Abintus Bio is headquartered in San Diego, US.

Abintus Bio

San Diego, US · Founded 2020 · Delaware corporation · 2 known investors

Find your way into Abintus Bio

174 people in our graph share verified history with the Abintus Bio team — schools, employers, funds. One of them is your warm intro.

Andreas Schropferunlockedknows Douglas J. Jolly · together at University of Glasgow

×7knows the team · via University of Glasgow

×4knows the team · via Weizmann Institute of Science

Biotech

Founders & leadership

Abintus Bio was founded in 2020 by Douglas J. Jolly.

Douglas J. Jolly inFounderDouglas J. Jolly is a founder of Abintus Bio with three decades of experience in gene therapy development and manufacturing. He has held senior executive roles at Viagene, Chiron, Oxford BioMedica, Advantagene, and Tocgen, and has authored over 125 scientific publications and holds more than 50 patents.

Carlos E. IbanezNamed on SEC filing

Robert Anthony WilliamsonNamed on SEC filing

Troy WilsonNamed on SEC filing

Michael MartinNamed on SEC filing

Nicholas A. Boyle, Ph.D.Named on SEC filing

Investors · 2

BioBritLa Jolla

Takeda VenturesreportedCambridge · $1M – $5M

Reported raises · per SEC filings

Form D private placements

$13.7M disclosed across 1 round · 2022

▶$13.7MraisedAug 2022 · 37 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Carlos E. IbanezExecutive Officer
Robert Anthony WilliamsonDirector
Troy WilsonDirector
Michael MartinDirector
Nicholas A. Boyle, Ph.D.Executive Officer, Director

Offering amount: $15.7M
Amount sold: $13.7M
First sale: Aug 2022
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Disseminated Mycobacterium avium Complex Infection Following CD3/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma | Open Forum Infectious Diseases | Oxford Academicacademic.oup.com · Aug 2024

Abintus Bio Appoints Hebrew University Researcher Lior Nissim, Ph.D., As Head of Synthetic Biology and Concurrently Enters Agreement for Next-Generation, Synthetic Biology Technology to Enable In Vivo Genetic Medicinesbusinesswire.com · Jan 2023

San Diego California based Abintus Bio is raising $15,652,623.00 in New Equity Investment. - intelligence360intelligence360.news · Aug 2022

Abintus Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference - BioSpacebiospace.com · Jan 2022

Abintus Bio Enters Technology Agreement to Enhance In Vivo-Reprogrammed CAR Cell Potency and Durability Against Hematologic Malignancies and Solid Tumorsbusinesswire.com · Nov 2021

Abintus Bio Enters Technology Agreement to Enhance In Vivo-Reprogrammed CAR Cell Potency and Durability Against Hematologic Malignancies and Solid Tumors - BioSpacebiospace.com · Nov 2021

Frequently asked questions

Who founded Abintus Bio?: Abintus Bio was founded by Douglas J. Jolly in 2020.
Who are Abintus Bio's investors?: Abintus Bio's investors include BioBrit, Takeda Ventures.
How much funding has Abintus Bio raised?: Abintus Bio has disclosed $13.7M raised across 1 round.
Where is Abintus Bio headquartered?: Abintus Bio is headquartered in San Diego, US.